4858美高梅重复好药片,中国制

按:中国制药有哪里优势?本文将为您解析中国药企正在成为全球新药开发关键力量之几个原因。本文译自《经济学人》3月18日刊。

4858美高梅 1

来华

​The pharma business

A better pill from China

复好之药丸来自华夏

Chinese pharma firms are starting to develop new drugs for the global
market

中国制药公司起为中外市场开新的药

  1. WALK into the Shanghai laboratories of Chi-Med, a biotech firm, and
    you encounter the sort of shiny, cutting-edge facilities common
    in any major pharma company in America, Europe or Japan.
    Chi-Med(和黄药业)has just had positive results in a late-stage
    trial of its drug for colorectal cancer, which is called
    Fruquintinib. If the drug is approved both in China and in Western
    markets it could be the very first prescription drug to be designed
    and developed entirely in China that will be on a path to global
    commercialisation.
    1)走上前上海跟黄药业的实验室,一小生物技术公司,你晤面不期而遇那些当欧美要日本另外大型制药企业都不行宽泛的闪光、尖端的设备。和黄中国药业在直肠癌药物之杪试验是阳性结果,这种药为称之为呋喹替尼。如果该药在炎黄以及当净土市场都吃认可(生产),它恐怕是全在华夏给规划和支出之率先批处方药,中国(药业)将走向全球商业化道路。

  2. Given China’s ageing population, higher incomes and rising demand
    for health care it is clear why innovation in drugs is a priority
    for the country. Its national market for drugs has grown rapidly in
    recent years to become the world’s second-largest. It could grow
    from $108bn in 2015 to around 167bn dollars by 2020, according to an
    estimate from America’s Department of Commerce. By comparison,
    America spends about $400bn a year on drugs.
    2)鉴于中国之老龄化人口、更胜个人收入和连上升的医疗保健需求,为何在药物方面的翻新成为这国家的当务之急就是清清楚楚了。近年来,中国药的国内市场快速增强,已经改为世界第二分外药品市场。据美国商务部估算,它可打2015年之1080亿美元增长至2020年的光景1670亿美元。相比之下,美国于药物及等同年花了大概4000亿美元。

  3. Chinese firms mainly sell cheap,** generic medicines** that earn
    only razor-thin margins. The pharma industry is extremely
    fragmented, with thousands of tiny manufacturers and distributors.
    That helps explain the limited amount of finance that is available
    for investment in new medicines. Most Chinese pharma firms devote
    less than 5% of sales to R&D, according to a report last year from
    the World Health Organisation (big global drug firms typically spend
    14%-18% of sales on R&D). And the bulk of that spending goes to
    research into generics.
    3)中国信用社根本销售便宜的通用名药品,只能赚到轻的盈利。制药行业多分散,有数以千计的小型制造商与分销商。这促进分解可用来新药投资之本钱怎么少。根据世界卫生组织去年的平客报告,大多数中国制药公司投入了未顶5%之销售额用于研发,(大型全球制药公司一般而言以研发及花销售额的14%到18%)。这些支出大部分用以研究通用名药品。

通用名药品(英语:Generic
Drug、又如国际非专有名称药物、非专利药、学名药)是由各政府规定的、国家药典或药物标准应用的官药物。
从未有过专利的通用名药品以专利未过(一般为20年,除去研究与尝试时间,大致7-12年)时莫被允许销售(特殊情形除了),但若是专利了期别的厂商即使见面进市场,可以大幅下降原本被专利限制药物之标价。目前非专利药物生产大国也印度,这些非专利药生产厂的特性在于后发销售,本地药商仿效西方大型药厂已经做好的结果,一般还见面在以同样之化合物之外调整有分,除了被特困的地区民众得到医治,印度厂商所生育的雅量药物还销售往外,产品以国际及发生无数第三世界国家遭受采用。
另外,Generic
Drug实际意义就是啊每当药理作用上跟专利药物相近的药物,通常厂商还是多或者有失用了优先药厂的有关经历。由于此类药品生产厂商不待向药物发明者支付专利费(包含在药品设计,临床试验等众多用),所以通用名药品以价钱上会相对好。——维基百科

  1. But things are changing quickly. The government is encouraging the
    industry to consolidate, chiefly by raising standards for the
    quality of new medicines. It is also improving the country’s
    regulatory infrastructure, which should make it more efficient, and
    faster, to develop drugs. The value of deals in the health-care
    sector has been increasing as a result. ChinaBio, a research firm,
    reckons that over $40bn of foreign and local money went into the
    life sciences in China in 2016. In the same year just three Chinese
    biotech firms—CStone, Innovent and Ascletis—together raised more
    than $500m of financing.
    4)但整套在迅速改变。政府当鼓励制药企合并,主要通过增强新药品质量标准的点子。它为以改善国家的监管基础设备,这应该使她再也便捷、更便捷地出药物。因此,医疗保健行业之交易价不断加码。一家美国钻局ChinaBio估计,2016年超越400亿美元的大千世界资金进去中国底生命科学(产业)。在同一年,仅三下中国生物科技公司——上海基石药业、苏州信达生物和杭州歌礼生物科技有限公司——就协同筹集了跨越5亿美元融资。

  2. Another boost is the arrival of talent from abroad, whether
    Chinese-born executives returning with a Western education or
    Westerners with experience of multinational pharmaceutical firms.
    Christian Hogg, the boss of Chi-Med—which was founded in 2000, has
    eight drugs in clinical development and listed on the NASDAQ stock
    exchange in 2016—used to work at Procter & Gamble, a global
    consumer-goods firm. Samantha Du, the firm’s very first scientific
    officer, was formerly an executive at Pfizer, an American pharma
    giant. Now known as the godmother of Chinese biopharma, she used to
    manage health-care investments for Sequoia Capital, a Silicon Valley
    venture-capital firm. In 2013 she helped found Zai Lab, which
    licenses late-stage drugs from Western pharma companies to
    develop and sell in China. Zai Lab also aims to develop innovative
    medicines in immuno-oncology.
    5)另一个推要素是异域人才的到来,无论是接受西方教育还要回国的神州管理人员,还是来跨国制药企业更的净土人士。贺隽是白手起家于2000年的跟黄药业的老板娘,该铺面持有医疗开发的八栽药,并于2016年于纳斯达克股票交易所上市。他已当全世界消费品企业宝洁公司做事。该商厦的第一各类专业出身的高管杜莹曾是美国制药业巨头辉瑞制药公司的执行官。现在它们为誉为中国生物制药的教母,她就为同样下硅谷风险投资企业——红杉资本管理医疗保健投资。2013年她拉创建(总部位于上海之生物科技公司)再煲医药,该企业自从西方制药企业取得季药物许可证因当中华研发并销售。再煲医药还从为开发免疫肿瘤学地方的创新药物。

  3. Another firm attracting attention is BeiGene, an oncology firm based
    in Beijing, which has four clinical-stage drug candidates and which
    raised $158m in an IPO last year. Chi-Med’s Fruquintinib may even be
    beaten in the race to approval in America and Japan by a cancer drug
    called Epidaza from Chipscreen Biosciences of Shenzhen. China
    approved it in 2015.
    6)另一样寒引人关注的凡总部在首都、从事抗癌药研发的百帮困神州生物制药公司,它发四种植医疗阶段的候选药物,并以去年首不善公开募股到1.58亿美元。和黄中国药业的呋喹替尼可能当美国跟日本拿走特许的竞中吃深圳微芯生物科技的抗癌药物Epidaza所击溃。而中国受2015年就特许了其(前者的研发)。

  4. It is too early to say whether these innovative firms will remain
    rarities. Only a few large ones have emerged, since the industry
    is resisting consolidation. But the size of the local market will
    itself help the industry grow. And developing a drug in China is far
    cheaper than it is in America or Europe. Given the outrage at the
    high cost of drugs in America, in particular, there is every
    incentive
    for Chinese firms to develop medicines for the global
    market.
    7)这些创造时号是否会连续成为寥寥可数尚言之过早。只有个别坏商厦一度崭露头角,因为该行业一直以抵制整合。但地面市场的范围本身将推进行业提高。在炎黄付出同栽新药(的本金)远较欧美低廉。尤其是,鉴于美国药物价格昂贵引起愤怒,中国铺为天下市场开发药品的遐思十足


试着翻译以下句子:
1、鉴于中国底老龄化人口、更胜似个人收入和不断上升之健康照护需求,为何在药品方面的创新成为这个国度之当务之急就是清楚了。

2、另一个推动因素是异域人才的来到,无论是接受西方教育而回国的华管理人员,还是有跨国制药公司更的极乐世界人士。

3、尤其是,鉴于美国药物价格昂贵引起愤怒,中国小卖部也天下市场开发药品的想法十足

原文出处:经济学人杂志

翻译:追梦心;校对:七呵夫;编辑:七呵夫

本译文仅供个人研习、欣赏语言的用,谢绝任何转载以及用于其他商业用途。本译文所波及法律后果均是因为我负责。本人同意简书平台在接获有关著作权人的关照后,删除文章。

相关文章